RBC Cuts Price Target on Genmab to DKK2,000 From DKK2,300, Keeps Outperform Rating

Published on 29/05/2025 at 11:25

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Genmab A/S

Genmab A/S Announces Sales Results of Darzalex for Second Quarter of 2025	07-16	CI
Genmab says net sales of Darzalex in Q2 $3,539 mln	07-16	RE
Johnson & Johnson Reports Q2 Worldwide Sales of Cancer Drug Darzalex	07-16	MT
Genmab Reports Higher Q2 Sales for Multiple Myeloma Drug Darzalex	07-16	MT
Genmab: Darzalex Sales Surpass $3.5 Billion in Q2	07-16	FW
Baptista Research Begins Genmab Coverage at Outperform	07-11	MT
Genmab Announces Changes to Its Executive Committee	07-01	CI
Genmab's Chief Legal Officer Steps Down; Successor Named	07-01	MT
UBS Lowers Price Target for Genmab to 2,500 Danish Kroner, Reiterates Buy Recommendation	06-25	FW
Genmab A/S, Q1 2025 Earnings Call, May 08, 2025	06-17
Genmab Says Experimental Combination Trial Shows High Response Rates in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma	06-16	MT
Genmab's Epcoritamab Combination Shows High Response Rates in Cancer Patients	06-16	MT
Genmab A/S Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (L) Eligible for Autologous Stem Cell Transplantation	06-15	CI
Genmab A/S Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 08:00 AM	06-09
AlphaValue/Baader Europe Keeps Genmab at Buy, Boosts Price Target on Pipeline Strength	06-09	MT
GENMAB : Beaten up share price offers an opportunity	06-06
Genmab's Rina-S shows promising efficacy in difficult-to-treat uterine cancer	06-03	FW
Sector Update: Health Care Stocks End Higher Late Afternoon	06-02	MT
Genmab Says New Trial Data Shows 'Encouraging Anti-Tumor Activity' for Rinatabart Sesutecan	06-02	MT
Genmab A/S Announces Investigational Rinatabart Sesutecan (Rina-S) Demonstrates Encouraging Anti-Tumor Activity Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL-01 Trial	06-02	CI
RBC lowers target price for Genmab to DKK 2,000 (2,300), reiterates outperform rating - BN	05-30	FW
RBC Cuts Price Target on Genmab to DKK2,000 From DKK2,300, Keeps Outperform Rating	05-29	MT
Deutsche Bank lowers target price for Genmab to DKK 1,750 (1,900), reiterates buy recommendation	05-23	FW
Redburn lowers target price for Genmab to DKK 2,700 (2,750), reiterates buy recommendation - BN	05-23	FW
Genmab A/S to Present New and Updated Results from Its Robust Epcoritamab (Epkinly®) Development Program At the 2025 European Hematology Association Congress	05-14	CI